市場調查報告書
商品編碼
1470946
mRNA 平台市場:按 mRNA 類型、適應症、應用和最終用戶分類 - 2024-2030 年全球預測mRNA Platform Market by mRNA Type (Nucleoside-Modified mRNA, Self-Amplifying mRNA, Unmodified mRNA), Indication (Autoimmune Diseases, Cancer, Infectious Diseases), Application, End-User - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年mRNA平台市場規模為135.2億美元,2024年達163.3億美元,預計2030年將達到527.1億美元,複合年成長率為21.44%。
mRNA(傳訊RNA)平台是醫學和生物技術領域的一種新方法,主要用於疫苗和治療方法的開發。 mRNA 充當細胞中 DNA 和各種身體功能所必需的蛋白質之間的分子中介。 mRNA 平台利用合成 mRNA 引導細胞產生特定蛋白質,例如觸發免疫反應或刺激細胞修復,而不會改變細胞的 DNA。 mRNA 平台具有加速疫苗開發和生產的能力,由於全球對有效、快速生產疫苗的需求不斷成長,對 mRNA 平台的需求也不斷增加。只需改變疫苗中 mRNA 的序列,即可客製化 mRNA 療法來對抗從感染疾病到癌症等多種疾病。這種多功能性為針對各種病症的個人化醫療和治療方法開闢了新途徑。然而,mRNA疫苗和治療藥物需要超低溫儲存才能保持穩定性,這給配送帶來了挑戰,特別是在基礎設施有限的地區。將 mRNA 有效地遞送至細胞而不發生分解是一個相當大的障礙。研究人員不斷發現和改進脂質奈米顆粒和其他遞送方法來保護 mRNA,直到其到達目標細胞。除了預防性疫苗外,mRNA 技術也正在研究用於癌症治療、遺傳性疾病和自體免疫疾病等治療應用。
主要市場統計 | |
---|---|
基準年[2023] | 135.2億美元 |
預測年份 [2024] | 163.3億美元 |
預測年份 [2030] | 527.1億美元 |
複合年成長率(%) | 21.44% |
mRNA 類型:核苷修飾的 mRNA 可以透過減少副作用和提高穩定性來平衡免疫反應的有效性。
核苷修飾的 mRNA 會改變 RNA 的組成部分(核苷),以逃避人體的自然防禦,這種防禦會快速分解 mRNA 或引發不必要的免疫反應。透過修飾這些核苷,科學家可以提高 mRNA 的穩定性和翻譯能力,從而使治療和疫苗訊息更有效地傳遞到人類細胞。這種類型的 mRNA 已廣泛用於 COVID-19 疫苗的開發,因為它能有效引發強烈且持久的免疫反應,且副作用最小。自我擴增的mRNA通常源自於正鏈RNA病毒的基因組,並且具有在宿主細胞內自我複製的獨特能力。這種放大過程意味著可以施用更小的劑量,這可能會降低製造成本並提高可用性。這種 mRNA 不僅編碼感興趣的抗原(例如,需要產生免疫反應的病毒部分),還編碼病毒複製機制,允許長期產生抗原,使其更能誘導強烈的免疫反應。未修飾的 mRNA 是用於醫學應用的最簡單的 mRNA 形式。它不像核苷修飾的 mRNA 那樣經歷核苷修飾。雖然這使得產生 mRNA 變得更容易,但未修飾的 mRNA 更容易分解,並可能誘導更強的先天免疫反應,為免疫系統提供強大的刺激,但也可能產生副作用。
最終用戶:製藥公司廣泛參與 mRNA 平台的行銷和許可。
醫院和診所主要使用基於 mRNA 的治療和疫苗作為患者照護服務的一部分。他們處於使用 mRNA 平台開發的疫苗的第一線,並在公共衛生工作中發揮關鍵作用,特別是在大流行期間。此外,醫院可以在專門護理下提供針對某些疾病的基於 mRNA 的治療方法。製藥公司正在為基於 mRNA 的藥物和疫苗的開發、測試和商業化做出重大貢獻。他們正在大力投資研發 (R&D),以探索 mRNA 技術在治療多種疾病方面的潛力,包括感染疾病以及癌症和遺傳性疾病。這些公司處理成功的 mRNA治療方法的臨床試驗、監管核准和大規模生產的複雜過程。因此,製藥公司是推進 mRNA 平台並將新治療方法從實驗室推向市場的關鍵機構。研發機構和學術機構進行基礎研究,以了解細胞中 mRNA 的機制,探索改善 mRNA 遞送和穩定性的創新方法,並開發該技術的新應用。這些研究機構經常與製藥公司合作,提供進一步開發基於 mRNA 的治療方法所需的基礎知識。儘管這些機構不參與商業化過程,但它們在擴大對 mRNA 及其潛在應用的科學理解方面所發揮的作用是有價值的。
區域洞察
美洲,特別是美國和加拿大,由於醫療保健支出高、醫療保健基礎設施完善以及對研究和創新的高度重視,為 mRNA 平台呈現出成熟的格局。美洲地區是多家生物技術和製藥公司的所在地,這些公司經常投資研發項目,以提高 mRNA 平台的安全性、效率和性能。歐盟國家在支持 mRNA 研究和產品核可的法律規範方面處於領先地位。英國、德國和法國等國家在政府、學術界和私營部門之間的合作推動下擁有強大的生物技術部門。歐洲藥品管理局 (EMA) 在促進基於 mRNA 的治療方法的快速核准方面發揮著至關重要的作用。亞太地區是 mRNA 平台技術快速發展的地區,以中國、日本和印度為首。該地區人口眾多,對疫苗和治療方法(包括 mRNA 平台)有巨大需求。政府對改善醫療基礎設施的支持非常重要,而對先進治療方法的認知的提高為 mRNA 平台的擴展提供了重大機會。亞太地區作為疫苗和藥物治療藥物製造地的戰略地位也為加速 mRNA 平台的採用提供了有利的框架。
FPNV定位矩陣
FPNV定位矩陣對於評估mRNA平台市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可對 mRNA 平台市場供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該行業競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4.競爭評估與資訊:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5. 產品開發與創新:提供對未來技術、研發活動和突破性產品開發的見解。
1.mRNA平台市場的市場規模與預測是多少?
2. mRNA 平台市場預測期間需要考慮投資的產品、細分市場、應用程式和領域有哪些?
3.mRNA平台市場的技術趨勢和法規結構是什麼?
4.mRNA平台市場主要廠商的市場佔有率為何?
5.進入mRNA平台市場合適的形式和策略手段是什麼?
[194 Pages Report] The mRNA Platform Market size was estimated at USD 13.52 billion in 2023 and expected to reach USD 16.33 billion in 2024, at a CAGR 21.44% to reach USD 52.71 billion by 2030.
The mRNA (messenger RNA) platform is a novel approach in the field of medicine and biotechnology, primarily utilized for the development of vaccines and therapeutics. mRNA serves as a molecular intermediary between the DNA in cells and the proteins that are essential for various bodily functions. The mRNA platform leverages synthetic mRNA to instruct cells to produce specific proteins that can trigger an immune response or stimulate cell repair without altering the cell's DNA. The ability of mRNA platforms to accelerate the development and production of vaccines and the rising global need to effectively and quickly produce vaccines has driven the need for mRNA platforms. mRNA therapies can be tailored to fight a wide array of diseases, from infectious diseases to cancer, by simply modifying the mRNA sequence the vaccines carry. This versatility opens up new avenues in personalized medicine and treatments for various conditions. However, mRNA vaccines and therapeutics require ultra-cold storage to remain stable, presenting logistical challenges in distribution, particularly in regions with limited infrastructure. Efficiently delivering mRNA into cells without degradation is a considerable hurdle. Researchers are continuously working on finding and improving lipid nanoparticles and other delivery methods to protect the mRNA until it reaches the target cells. Beyond preventive vaccines, mRNA technology is being explored for therapeutic applications, including cancer treatment, genetic disorders, and autoimmune diseases.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 13.52 billion |
Estimated Year [2024] | USD 16.33 billion |
Forecast Year [2030] | USD 52.71 billion |
CAGR (%) | 21.44% |
mRNA Type: Ability of nucleoside-modified mRNA to balance immune response efficacy with reduced side effects and offer enhanced stability
Nucleoside-modified mRNA involves the alteration of RNA building blocks (nucleosides) to evade the body's natural defenses, which might otherwise rapidly degrade the mRNA or trigger an unwanted immune response. By modifying these nucleosides, scientists can enhance the stability and translational capacity of the mRNA, making it more effective in delivering the therapeutic or vaccine message to the body's cells. This type of mRNA has been widely used in developing COVID-19 vaccines due to its efficiency in producing a strong and lasting immune response with minimal side effects. Self-amplifying mRNA, often derived from the genome of positive-strand RNA viruses, has the unique ability to replicate itself within the host cells. This amplification process means that smaller doses can be administered, potentially reducing production costs and improving accessibility. In addition to encoding the antigen of interest (such as parts of a virus against which an immune response is desired), this mRNA also encodes the viral replication machinery, enabling the prolonged production of the antigen and thereby inducing a stronger and longer-lasting immune response. Unmodified mRNA is the most straightforward form of mRNA used in medical applications. It does not undergo the nucleoside modifications seen in nucleoside-modified mRNA. While this simplifies its production, unmodified mRNA is more susceptible to degradation and may induce stronger innate immune responses, providing a potent stimulant for the immune system but also potentially leading to adverse effects.
End-User: Extensive involvement of pharmaceutical companies in the marketing and authorization of mRNA platforms
Hospitals and clinics primarily use mRNA-based treatments and vaccines as part of their patient care services. They are at the forefront of administering vaccines developed using the mRNA platform, playing a crucial role in public health initiatives, especially during pandemics. Additionally, mRNA-based therapies for certain diseases might be provided in hospital settings under specialized care. Pharmaceutical companies are instrumental in the development, testing, and commercialization of mRNA-based drugs and vaccines. They invest heavily in research and development (R&D) to explore the potential of mRNA technology in treating a wide array of diseases, beyond just infectious diseases to include cancer and genetic disorders. These companies handle the complex processes of clinical trials, regulatory approvals, and mass production of successful mRNA treatments. Thus, pharmaceutical companies are key institutions in advancing the mRNA platform and bringing new therapies from the lab to the market. Research and academic institutions conduct fundamental research to understand the mechanism of mRNA within the cell, explore innovative approaches to improve mRNA delivery and stability, and develop new applications for this technology. These institutions often collaborate with pharmaceutical companies and provide the foundational knowledge necessary for further development of mRNA-based treatments. While they are not involved in the commercialization process, their role in expanding the scientific understanding of mRNA and its potential applications is valuable.
Regional Insights
The Americas, particularly the United States and Canada, present a mature landscape for the mRNA platform, driven by the high healthcare expenditure, sophisticated healthcare infrastructure, and a strong focus on research and innovation. The Americas region is characterized by the presence of several biotechnology and pharmaceutical companies that frequently invest in R&D programs to improve the safety, efficiency, and performance of mRNA platforms. EU countries lead in regulatory frameworks supporting mRNA research and product approvals. Nations such as the U.K., Germany, and France have strong biotech sectors that are propelled by collaborative efforts between governments, academia, and private sectors. The European Medicine Agency (EMA) plays a pivotal role in facilitating the swift approval of mRNA-based treatments. APAC region is a rapidly evolving landscape for mRNA platform technologies driven by China, Japan, and India. The region's significant population base presents a vast need for vaccines and therapeutic treatments, including mRNA platforms. Government support for improving the healthcare infrastructure notably and a growing awareness of advanced treatment modalities present significant opportunities for the expansion of mRNA platforms. APAC's strategic position as a manufacturing hub for vaccines and drug therapeutics also serves to create a conducive framework for driving the adoption of mRNA platforms.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the mRNA Platform Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the mRNA Platform Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the mRNA Platform Market, highlighting leading vendors and their innovative profiles. These include Accanis Biotech F&E GmbH & Co KG, Aldevron, LLC by Danaher Corporation, Arcturus Therapeutics, Inc., Argos Therapeutics, Inc., AstraZeneca plc, Avectas Limited, BioNTech SE, Catalent, Inc., CRISPR Therapeutics AG, CureVac N.V., Daiichi Sankyo, Dicerna Pharmaceuticals, Inc by Novo Nordisk A/S, eTheRNA, ethris GmbH, Gritstone bio, In-Cell-Art, Merck & Co., Inc., Moderna, Inc., Pfizer Inc., Precision BioSciences, Inc., Regulus Therapeutics Inc., Sangamo Therapeutics, Inc., Sanofi S.A., Tiba Biotech LLC, and Verve Therapeutics.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the mRNA Platform Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the mRNA Platform Market?
3. What are the technology trends and regulatory frameworks in the mRNA Platform Market?
4. What is the market share of the leading vendors in the mRNA Platform Market?
5. Which modes and strategic moves are suitable for entering the mRNA Platform Market?